Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGX818 (encorafenib) in BRAF V600 mutant advanced non-small cell lung cancer
2013-005014-34Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Apr 2014; status: terminated.
02
Drugs
encorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-005014-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005014-34.